FDx Advisors Inc. grew its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP – Get Rating) by 71.5% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 2,557 shares of the company’s stock after buying an additional 1,066 shares during the quarter. FDx Advisors Inc.’s holdings in Medpace were worth $557,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Marshall Wace LLP bought a new stake in shares of Medpace during the 1st quarter worth $99,000. FMR LLC increased its position in Medpace by 6,709.3% during the first quarter. FMR LLC now owns 37,247 shares of the company’s stock worth $2,196,000 after acquiring an additional 36,700 shares during the period. Private Advisor Group LLC raised its position in shares of Medpace by 108.5% during the third quarter. Private Advisor Group LLC now owns 2,614 shares of the company’s stock valued at $494,000 after buying an additional 1,360 shares during the last quarter. New York State Teachers Retirement System raised its holdings in Medpace by 5.0% in the 3rd quarter. New York State Teachers Retirement System now owns 31,230 shares of the company’s stock valued at $5,911,000 after acquiring an additional 1,482 shares in the last quarter. Finally, Fisher Asset Management LLC raised its stake in shares of Medpace by 12.0% in the third quarter. Fisher Asset Management LLC now owns 328,306 shares of the company’s stock valued at $62,142,000 after purchasing an additional 35,282 shares in the last quarter. 96.88% of the stock is owned by institutional investors and hedge funds.
Shares of MEDP stock opened at $164.77 on Monday. The firm’s fifty day moving average price is $158.42 and its two-hundred day moving average price is $186.79. Medpace Holdings, Inc. has a 1 year low of $136.80 and a 1 year high of $231.00. The firm has a market capitalization of $5.80 billion, a P/E ratio of 34.26 and a beta of 1.48.
A number of brokerages have issued reports on MEDP. StockNews.com started coverage on Medpace in a report on Thursday, March 31st. They set a “buy” rating for the company. Zacks Investment Research downgraded shares of Medpace from a “buy” rating to a “hold” rating in a research note on Saturday, February 19th. Finally, Robert W. Baird upped their price objective on Medpace from $160.00 to $175.00 in a report on Thursday, March 17th.
Medpace Profile (Get Rating)
Medpace Holdings, Inc provides clinical research-based drug and medical device development services in North America, Europe, and Asia. It offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. The company also provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services.
- Get a free copy of the StockNews.com research report on Medpace (MEDP)
- PayPal Stock is Still Ready for Bargain Hunting
- It’s Personal: 3 Personal Care Stocks to Own in Volatile Markets
- Conagra Stock Has More Room to Grow
- 3 Recession-Proof Stocks to Buy Now
- MarketBeat: Week in Review 4/4 – 4/8
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.